Destina Genomica SL is part of a consortium formed by the Foundation for Biomedical Research of the Ramón y Cajal University Hospital (Madrid, Spain), the Advanced Photonic and Biofunctional Materials Group of the UAM (Autonomous University of Madrid, Spain) and led by the Spanish company Mecwins SA (Madrid) that has just received a grant of…
We are excited to announce a new project that changes the way we analyze miRNA-122. This small non-coding RNA is known as a biomarker for liver injury. With the support of the 2022 ICEX-Invest in Spain’s funding program, we are implementing the unique PCR-Free testing of miRNA-122 using DESTINA’s ChemiRNATM Tech reagents merged with AVAC…
DESTINA Genomics and Mecwins join forces to develop more reliable diagnostic tests Both biotechnology firms have signed a cross-licensing agreement to share technology to develop RNA quantification tests directly from biological samples. Initial tests will focus both on RNA biomarkers for drug-induced hepatotoxicity, nephrotoxicity and cardiotoxicity, and on therapeutic RNAs. Thanks to the combination…
DESTINA Genomica SL has joined @Science Exchange, the global platform for outsourced R&D reagents and services. For quotations on the supply of RNA profiling services and custom PNAs synthesis for your research, just contact us via our website. Orders on acceptance can then be made securely through https://www.scienceexchange.com/labs/destina-genomica-sl
DESTINA Genomics has a new redesigned and upgraded website at www.destinagenomics.com Now live, the modernised web design makes access easy to our product and services for PCR free, highly accurate and quantifiable detection of RNA Biomarkers. DESTINA’s unique patented chemistry and how it works is now explained using a 3D Video, with a dynamic new…
Novel molecular assay based on ‘Single Nucleotide Fingerprints’ (SNF) for the diagnosis and monitoring of Trypanosomatids. EDINBURGH, UK and GRANADA, Spain—July 21, 2017— Researchers at the Centre for Genomics and Oncological Research (GENYO) located in Granada, Spain, in collaboration with DestiNA have developed a novel assay for the diagnosis and monitoring of Trypanosomatids. The method…
Breakthrough Research Published in PLOS ONE Demonstrates Quantitative, PCR-Free Detection of MicroRNA LEXINGTON, Mass. and EDINBURGH, UK—July 5, 2017— Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, and DestiNA Genomics Ltd, a manufacturer of patented reagents for nucleic acid detection, today announced that PLOS ONE has…